Investment Analysts’ Recent Ratings Updates for Rezolute (RZLT)

Several brokerages have updated their recommendations and price targets on shares of Rezolute (NASDAQ: RZLT) in the last few weeks:

• 6/3/2026 – Rezolute had its “neutral” rating reaffirmed by Cantor Fitzgerald.
• 6/3/2026 – Rezolute was upgraded by Citigroup Inc. from “market perform” to “outperform”.
• 6/3/2026 – Rezolute was upgraded by Citizens Jmp from “market perform” to “outperform”. They now have a $11.00 price target on the stock.
• 6/3/2026 – Rezolute had its price target raised by Wedbush from $5.00 to $6.00. They now have an “outperform” rating on the stock.
• 6/2/2026 – Rezolute had its price target raised by BTIG Research from $5.00 to $6.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Rezolute had its price target raised by Maxim Group from $10.00 to $14.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Rezolute had its “buy” rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
• 5/16/2026 – Rezolute was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/14/2026 – Rezolute had its price target raised by Maxim Group from $4.00 to $10.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Rezolute had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.